Related Experiment Video
Updated: Jul 2, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Analysis of the Stability of 0.04% Mitomycin C Ophthalmic Solution under Various Storage Conditions
Yuma Nonomiya1,2, Koki Yamaguchi2, Yuta Yokoyama2
1Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Abstract:
A 0.04% mitomycin C (MMC) ophthalmic solution is not commercially available and is prepared in hospitals as required. The physical properties and stability of the MMC ophthalmic solution have not been clarified because of a lack of data. This study aimed to assess the stability of the MMC ophthalmic solution under various storage conditions. The MMC ophthalmic solution was prepared by dissolving 2 mg of MMC in 5 mL of saline solution. Each batch of ophthalmic solution was stored under three conditions [cold/shaded light, room temperature/shaded light, and room temperature/scattered light (approximately 4000 lx)], and MMC concentration was determined using high-performance liquid chromatography on days 0, 1, 3, 5, 7, 14, and 21. The expiry date was calculated based on the results of the degradation analysis. pH measurements and bacterial culture tests were conducted for each storage condition. The MMC concentrations on day 21 under cold/shaded light, room temperature/shaded light, and room temperature/scattered light were 340, 287, and 227 µg/mL, respectively. MMC concentrations decreased over time, and the decrease was highest when the samples were stored at room temperature and exposed to light, and lowest under cold conditions and protected from light. The pH of MMC solutions was 5.8 after preparation, which increased to 6.9 with time under all storage conditions. Culture tests did not detect any bacteria under any storage conditions. The MMC ophthalmic solution was most stable under cold/shaded conditions, and our study clarifies its expiry date for clinical use.
Insights
Hospital-prepared mitomycin C (MMC) ophthalmic solutions are unstable. Storing MMC solutions in the cold and shaded significantly enhances stability, determining its clinical use expiry date.
Area of Science:
- Ophthalmology
- Pharmaceutical Sciences
- Chemical Stability
Background:
- 0.04% mitomycin C (MMC) ophthalmic solution is prepared extemporaneously in hospitals.
- Limited data exists on the physical properties and stability of this compounded ophthalmic preparation.
Purpose of the Study:
- To evaluate the stability of hospital-prepared mitomycin C (MMC) ophthalmic solution.
- To determine optimal storage conditions and establish an expiry date for clinical use.
Main Methods:
- Mitomycin C (MMC) ophthalmic solution was prepared and stored under varied conditions: cold/shaded light, room temperature/shaded light, and room temperature/scattered light.
- High-performance liquid chromatography (HPLC) was used to quantify MMC concentration over 21 days.
- pH measurements and bacterial culture tests were performed.
Main Results:
- MMC concentration decreased over time, with the most significant degradation occurring at room temperature with light exposure.
- The lowest degradation rate was observed for solutions stored under cold conditions, protected from light.
- pH increased from 5.8 to 6.9, and no bacterial contamination was detected.
Conclusions:
- Mitomycin C (MMC) ophthalmic solution exhibits the greatest stability when stored under cold conditions and protected from light.
- This study provides crucial data for establishing a reliable expiry date for clinical application of compounded MMC ophthalmic solutions.
More Related Videos
07:20Simultaneous Visualization of the Dynamics of Crosslinked and Single Microtubules In Vitro by TIRF Microscopy
Published on: February 18, 2022
06:26Author Spotlight: Advancing Eye Physiology Research via a Multi-Channel Flow Culture for Optimal Tissue Maintenance and Real-Time Assessment
Published on: July 14, 2023
Related Concept Videos
Drug Product Stability
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Ophthalmic Drug Delivery Systems